Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)

NCT00310388 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00310388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00310388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Terminated
Start date
July 5, 2006
Completion date
May 24, 2018
Enrollment
376 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy